Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2015 from OUS - Molecular Genetic Studies of Breast and Ovarian Cancer
36 publications found
Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer
Genes (Basel), 6 (3), 878-900
DOI 10.3390/genes6030878, PubMed 26393654
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
Genome Med, 7 (1), 21
DOI 10.1186/s13073-015-0135-5, PubMed 25873999
Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas
BMC Cancer, 15, 524
DOI 10.1186/s12885-015-1510-8, PubMed 26183823
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN
PLoS One, 10 (5), e0126371
DOI 10.1371/journal.pone.0126371, PubMed 25955013
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study
BMC Cancer, 15, 468
DOI 10.1186/s12885-015-1479-3, PubMed 26062614
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1
Sci Rep, 5, 17369
DOI 10.1038/srep17369, PubMed 26621817
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Am J Hum Genet, 97 (1), 22-34
DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
Nat Genet, 47 (11), 1294-1303
DOI 10.1038/ng.3412, PubMed 26414677
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer
Cancer Res, 75 (4), 698-708
DOI 10.1158/0008-5472.CAN-14-2637, PubMed 25649770
Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk
Cancer Epidemiol Biomarkers Prev, 24 (11), 1680-91
DOI 10.1158/1055-9965.EPI-15-0363, PubMed 26354892
Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
Int J Cancer, 138 (1), 87-97
DOI 10.1002/ijc.29684, PubMed 26174627
Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
Mol Oncol, 10 (1), 59-72
DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate
Pharmacogenomics J, 15 (5), 385-90
DOI 10.1038/tpj.2015.11, PubMed 25778468
DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer
Clin Epigenetics, 7, 75
DOI 10.1186/s13148-015-0094-0, PubMed 26213588
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
Genome Res, 25 (6), 814-24
DOI 10.1101/gr.190470.115, PubMed 25963125
Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer
Carcinogenesis, 36 (2), 256-71
DOI 10.1093/carcin/bgu326, PubMed 25586992
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium
Hum Genet, 135 (1), 137-54
DOI 10.1007/s00439-015-1616-8, PubMed 26621531
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
Breast Cancer Res, 17, 18
DOI 10.1186/s13058-015-0522-2, PubMed 25849327
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
J Natl Cancer Inst, 108 (2)
DOI 10.1093/jnci/djv315, PubMed 26586665
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
Nat Genet, 47 (4), 373-80
DOI 10.1038/ng.3242, PubMed 25751625
MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase
Mol Oncol, 9 (6), 1056-70
DOI 10.1016/j.molonc.2015.01.005, PubMed 25682900
A conditional transgenic mouse line for targeted expression of the stem cell marker LGR5
Dev Biol, 404 (2), 35-48
DOI 10.1016/j.ydbio.2015.05.002, PubMed 26003047
Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2
Hum Mol Genet, 24 (10), 2966-84
DOI 10.1093/hmg/ddv035, PubMed 25652398
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
Gynecol Oncol, 141 (2), 386-401
DOI 10.1016/j.ygyno.2015.04.034, PubMed 25940428
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
Genes Dev, 29 (12), 1298-315
DOI 10.1101/gad.263202.115, PubMed 26080815
Common germline polymorphisms associated with breast cancer-specific survival
Breast Cancer Res, 17, 58
DOI 10.1186/s13058-015-0570-7, PubMed 25897948
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells
Mol Oncol, 9 (10), 2054-62
DOI 10.1016/j.molonc.2015.10.003, PubMed 26607741
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
Mol Oncol, 10 (2), 303-16
DOI 10.1016/j.molonc.2015.10.011, PubMed 26590090
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients
BMC Cancer, 15, 978
DOI 10.1186/s12885-015-1957-7, PubMed 26674097
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
PLoS One, 10 (10), e0139965
DOI 10.1371/journal.pone.0139965, PubMed 26460974
From autonomy to community; new perspectives on tumorigenicity and therapy resistance
Cancer Treat Rev, 41 (10), 809-13
DOI 10.1016/j.ctrv.2015.10.004, PubMed 26519005
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
Cancer Res, 75 (12), 2457-67
DOI 10.1158/0008-5472.CAN-14-2012, PubMed 25862352
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
Breast Cancer Res, 17, 44
DOI 10.1186/s13058-015-0548-5, PubMed 25882602
MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth
Mol Oncol, 9 (7), 1287-300
DOI 10.1016/j.molonc.2015.03.001, PubMed 25907805